Update on the pathogenesis of diabetic neuropathy

被引：82

作者：

Irina G. Obrosova

机构：

[1] University of Michigan, Division of Endocrinology/Metabolism, Department of Internal Medicine, Ann Arbor, MI 48109-0678

来源：

Current Diabetes Reports | 2003年 / 3卷 / 6期

关键词：

Diabetic Neuropathy; Aldose Reductase; Peripheral Diabetic Neuropathy; Aldose Reductase Inhibitor; Nerve Blood Flow;

D O I：

10.1007/s11892-003-0005-1

中图分类号：

学科分类号：

摘要：

Peripheral diabetic neuropathy (PDN) affects up to 60% to 70% of diabetic patients, and is the leading cause of foot amputation. The pathogenesis of PDN involves multiple mechanisms. The findings obtained in 1999 to 2003 support the role of previously established mechanisms such as increased aldose reductase activity, nonenzymatic glycation or glyco-oxidation, activation of protein kinase C, enhanced oxidative stress, impaired neurotrophic support, and reveal the importance of new downstream effectors of oxidative injury. Those include mitogen-activated protein kinases and poly (ADP-ribose) polymerase that are activated by diabetes, and contribute to such neuropathic changes as motor and sensory nerve conduction deficits, decreased nerve blood flow, and energy failure. Further studies are needed to understand the role of other signaling pathways as well as interactions among previously discovered mechanisms in the pathogenesis of PDN. Copyright © 2003 by Current Science Inc.

引用

页码：439 / 445

页数：6

共 56 条

[1]

Boulton A.J., Treatments for diabetic neuropathy, Curr. Diabetes Rep., 1, pp. 127-132, (2001)

[2]

Cameron N.E., Eaton S.E., Cotter M.A., Tesfaye S., Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy, Diabetologia, 44, pp. 1973-1988, (2001)

[3]

Obrosova I.G., Van Huysen C., Fathallah L., Et al., An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense, FASEB J., 16, pp. 123-125, (2002)

[4]

Cameron N.E., Cotter M.A., Jack A.M., Et al., Protein kinase C effects on nerve function, perfusion, Na(+), K(+)-ATPase activity and glutathione content in diabetic rats, Diabetologia, 42, pp. 1120-1130, (1999)

[5]

Stevens M.J., Obrosova I., Cao X., Et al., Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy, Diabetes, 49, pp. 1006-1105, (2000)

[6]

Sima A.A., Sugimoto K., Experimental diabetic neuropathy: An update, Diabetologia, 42, pp. 773-788, (1999)

[7]

Williamson J.R., Chang K., Fringes M., Et al., Hyperglycemia pseudohypoxia and diabetic complications, Diabetes, 42, pp. 801-813, (1993)

[8]

Kuruvilla R., Eichberg J., Depletion of phospholipid arachidonoyl-containing molecular species in a human Schwann cell line grown in elevated glucose and their restoration by an aldose reductase inhibitor, J. Neurochem., 71, pp. 775-783, (1998)

[9]

Tomlinson D.R., Fernyhough P., Diemel L.T., Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factors, Diabetes, 46, SUPPL. 2, (1997)

[10]

Calcutt N.A., Campana W.M., Eskeland N.L., Et al., Prosaposin gene expression and the efficacy of a prosaposin-derived peptide in preventing structural and functional disorders of peripheral nerve in diabetic rats, J. Neuropathol. Exp. Neurol., 58, pp. 628-636, (1999)

← 1 2 3 4 5 6 →